Predicting Pathological Complete Response of Rectal Cancer With Magnetic Resonance(MR) Radiomics
Launched by SUN YING-SHI · Aug 1, 2017
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
We propose to develop and validate a radiomics model for individualized pCR evaluation after CRT in patients with LARC. We plan to use both pre- and post-CRT MRI data to construct the predictive radiomics model for evaluating if LARC patients achieve pCR after CRT. The ultimate aim is to select appropriate LARC patients for omission of surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • pathologically proved rectal cancer
- • locally advanced rectal cancer (≥T3 or N+)
- • a distance less than 12cm between the lower edge of tumor and the anal margin
- • no evidence of distant metastases
- • no prior anti-cancer therapy before treatment
- • scheduled to receive preoperative CRT
- Exclusion Criteria:
- • history or concurrent of other malignancy
- • incomplete preoperative CRT
- • failed to receive surgery or unavailable pCR assessment
- • poor quality of MR images for measurement
- • patient quit
About Sun Ying Shi
Sun Ying-Shi is a dedicated clinical trial sponsor specializing in innovative research and development within the pharmaceutical and biotechnology sectors. Committed to advancing healthcare solutions, Sun Ying-Shi focuses on conducting rigorous clinical trials that adhere to the highest ethical and regulatory standards. With a team of experienced professionals, the organization emphasizes collaboration and transparency, ensuring that the safety and well-being of participants are prioritized throughout the research process. Through its comprehensive approach, Sun Ying-Shi aims to bring groundbreaking therapies to market, ultimately improving patient outcomes and enhancing the quality of life for individuals worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Ying-Shi Sun
Study Chair
Peking University Cancer Hospital & Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials